PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
NEW YORK, May 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01171151/PharmaPoint-Multiple-Sclerosis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
Summary
F. Hoffmann-La-RocheMS has a low prevalence in India, which could be due to genetics or environmental factors. However, many physicians surveyed for this report mostly use the Poser criteria to diagnose patients, given the lack of current accessibility to sensitive diagnostic tools, such as MRI. Therefore, it is possible that the current rate of MS in India is grossly underestimated, meaning a large proportion of undiagnosed MS patients are not captured and provided adequate treatment. The major drivers of growth in this market will be the launch of oral DMTs and an increase in availability of advanced diagnostic tools, which will likely lead to increased diagnosis and treatment rates over the forecast period.
Scope
- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India Multiple Sclerosis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Introduction 102.1 Catalyst 102.2 Related Reports 113 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 143.1.3 Classification of Multiple Sclerosis 153.2 Symptoms 173.2.1 Prognosis 183.2.2 Quality of Life 194 Disease Management 204.1 Diagnosis 204.2 Treatment Overview 234.2.1 Management of Acute Relapse 244.2.2 Treatment with Disease-Modifying Therapies 244.2.3 Symptomatic Therapies 274.3 India 284.3.1 Diagnosis 284.3.2 Clinical Practice 285 Competitive Assessment 305.1 Overview 305.2 Strategic Competitor Assessment 315.3 Product Profiles – Major Brands 335.3.1 Betaseron/Betaferon (interferon beta-1b) 335.3.2 Avonex (interferon beta-1a) 385.3.3 Rebif (interferon beta-1a) 435.3.4 Copaxone (glatiramer acetate; copolymer-1) 475.3.5 Tysabri (natalizumab) 515.3.6 Gilenya/Imusera (fingolimod; FTY720) 565.3.7 Aubagio (teriflunomide) 615.3.8 Other Disease–Modifying Therapies 666 Opportunity and Unmet Need 676.1 Overview 676.2 Unmet Needs 686.2.1 Currently Available MS Drugs Only Provide Partial Benefits 686.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 696.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 706.2.4 Effective Treatments for Progressive MS Are Still Elusive 716.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 726.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 736.3 Unmet Needs Gap Analysis 746.4 Opportunities 756.4.1 Treatments for Progressive MS 756.4.2 Targeting Patients with Clinically Isolated Syndrome 757 Pipeline Assessment 767.1 Overview 767.2 Promising Drugs in Clinical Development 787.2.1 BG-12 (dimethyl fumarate; BG00012) 807.2.2 Lemtrada (alemtuzumab) 857.2.3 Laquinimod (ABR-215062) 917.2.4 Daclizumab High-Yield Process (HYP) 967.2.5 Ocrelizumab (RG1594) 1017.2.6 Siponimod (BAF-312) 1067.2.7 NU-100 (interferon beta-1b) 1107.2.8 Masitinib (AB-1010) 1147.2.9 Tcelna (imilecleucel-T) 1188 Market Outlook 1228.1 India 1228.1.1 Forecast 1228.1.2 Key Events 1248.1.3 Drivers and Barriers 1259 Appendix 1279.1 Bibliography 1279.2 Abbreviations 1389.3 Methodology 1429.4 Forecasting Methodology 1429.4.1 Diagnosed MS patients 1429.4.2 Percent Drug-Treated Patients 1439.4.3 Drugs Included in Each Therapeutic Class 1439.4.4 General Pricing Assumptions 1449.4.5 Individual Drug Assumptions 1459.4.6 Generic Erosion 1499.4.7 Pricing of Pipeline agents 1499.5 Physicians and Specialists Included in This Report 1509.6 Primary Research – Prescriber Survey 1519.7 About the Authors 1529.7.1 Analysts 1529.7.2 Global Head of Healthcare 1539.8 About GlobalData 1549.9 Contact Us 1549.10 Disclaimer 154
List of Tables
Table 1: Common Presenting Symptoms of Multiple Sclerosis 17Table 2: Factors That Can Affect Prognosis in Multiple Sclerosis 18Table 3: Revised 2010 McDonald Criteria for the Diagnosis of Multiple Sclerosis 21Table 4: Treatment Guidelines for Multiple Sclerosis 23Table 5: Top Three Disease-Modifying Therapies Prescribed for Multiple Sclerosis by Market 25Table 6: Pharmacotherapy for Common Multiple Sclerosis Symptoms 27Table 7: Disease-Modifying Drugs for the Treatment of Multiple Sclerosis, 2012 32Table 8: Product Profile – Betaseron 34Table 9: Betaseron/Betaferon SWOT Analysis, 2012 37Table 10: Product Profile – Avonex 39Table 11: Avonex SWOT Analysis, 2012 42Table 12: Product Profile – Rebif 44Table 13: Rebif SWOT Analysis, 2012 46Table 14: Product Profile – Copaxone 48Table 15: Copaxone SWOT Analysis, 2012 50Table 16: Product Profile – Tysabri 52Table 17: Tysabri SWOT Analysis, 2012 55Table 18: Product Profile – Gilenya 57Table 19: Gilenya SWOT Analysis, 2012 60Table 20: Product Profile – Aubagio 62Table 21: Aubagio SWOT Analysis, 2012 65Table 22: Summary of Alternative MS DMTs, 2012 66Table 23: Overall Unmet Needs – Current Level of Attainment 67Table 24: Clinical Unmet Needs – Gap Analysis, 2012 74Table 25: Multiple Sclerosis – Phase Pipeline, 2012 78Table 26: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 79Table 27: Product Profile – BG-12 81Table 28: BG-12 SWOT Analysis, 2012 84Table 29: Product Profile – Lemtrada 86Table 30: Lemtrada SWOT Analysis, 2012 90Table 31: Product Profile – Laquinimod 92Table 32: Laquinimod SWOT Analysis, 2012 95Table 33: Product Profile – Daclizumab High-Yield Process 97Table 34: Daclizumab SWOT Analysis, 2012 100Table 35: Product Profile – Ocrelizumab 102Table 36: Ocrelizumab SWOT Analysis, 2012 105Table 37: Product Profile – Siponimod 106Table 38: Siponimod SWOT Analysis, 2012 109Table 39: Product Profile – NU-100 111Table 40: NU-100 SWOT Analysis, 2012 113Table 41: Product Profile – Masitinib 114Table 42: Masitinib SWOT Analysis, 2012 117Table 43: Product Profile – Tcelna 119Table 44: Tcelna SWOT Analysis, 2012 121Table 45: Sales Forecasts ($m) for Multiple Sclerosis in India, 2012–2022 123Table 46: Key Events Impacting Sales for Multiple Sclerosis in India, 2012 124Table 47: Multiple Sclerosis Market in India – Drivers and Barriers, 2012 125Table 48: Physicians Surveyed, By Country 151
List of Figures
Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis 16Figure 2: Expanded Disability Status Scale (EDSS) 22Figure 3: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies 26Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012–2022 78Figure 5: Sales for Multiple Sclerosis in India by Drug Class, 2012-2022 124
To order this report:Pathology Industry: PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article